Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07625930

RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial

Esophageal and gastroesophageal junction cancers are serious diseases with limited cure rates, even when patients receive chemotherapy and surgery. New ways to improve treatment are urgently needed.

This study will test whether adding a commonly used cholesterol-lowering medication, simvastatin, to standard cancer treatment can improve outcomes. Simvastatin is widely used, safe, and inexpensive. Research suggests that it may also slow cancer growth by blocking pathways that cancer cells rely on for survival.

In this trial, patients will receive standard chemotherapy (with or without immunotherapy) before surgery. Half of the patients will also take simvastatin daily for up to two years. Researchers will compare how well tumors respond to treatment and whether patients remain cancer-free longer.

If successful, this approach could offer a simple and accessible way to improve survival for patients with these cancers without adding significant side effects or cost.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Gastroesophageal Adenocarcinoma Digestive System Diseases Digestive System Neoplasms Esophageal Diseases Esophageal Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Head and Neck Neoplasms Neoplasms Neoplasms by Site

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed, informed consent.
  • Age, 18 years or older.
  • Histological diagnosis of adenocarcinoma or poorly differentiated carcinoma of the esophagus or EGJ.
  • The tumour must be deemed potentially resectable by the surgical team. This assessment is based on complete staging imaging studies (detailed below) - clinical staging of the tumor and ruling out metastatic disease.
  • Locally advanced disease as defined per AJCC/UICC 8th edition37: stage IIA, IIB, III, IVA (T1-4a N2-3).
  • Eligibility for standard-of-care perioperative systemic therapy with FLOT+/-D.
  • Life expectancy greater than 3 months.
  • ECOG performance status < 2.

Exclusion criteria

  • Prior esophageal or gastric malignancy.
  • History of allergic reactions to simvastatin or atorvastatin or similar chemical or biological compounds.
  • Ongoing cholesterol-lowering therapy (statins, fibrates, ezetimibe, PCSK9 inhibitors), in which case the patient is offered enrollment in the observational arm.
  • Hepatic dysfunction (alanine aminotransferase level more than three times the upper limit of the normal range) or renal dysfunction (creatinine level more than three times the upper limit of the normal range).
  • Predisposing factors for rhabdomyolysis: hypothyroidism, reduced renal function, muscle disease, or excessive alcohol consumption AND creatine kinase up to less than five times the upper limit (measured in the presence of predisposing factors).
  • Concurrent medication with potent CYP3A4-inhibitors, e.g. ketokonazole, erythromycin, gemfibrozil, cyclosporine, or danazol.
  • Pre-existing medical conditions precluding treatment, including any contraindication systemic chemotherapy or major surgery.
  • Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule, discussed before registration in the trial.
  • Pregnant and breastfeeding women.
  • Unwillingness to undergo per-protocol investigations or treatments.

Treatment and study plan

FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)

Drug

Standard of care neoadjuvant FLOT

simvastatin

Drug

Investigational drug added to standard of care FLOT or FLOT+D

Durvalumab

Drug

Standard of care Durvalumab added to FLOT regimen.

Primary outcomes

  1. MPR

    Time frame: From enrolment to surgical pathology assessment, 16 weeks

    Major Pathological Response

Secondary outcomes

  1. Statin-enhanced toxicity of standard-of-care regimen, specifically grade 3 or 4 adverse events

    Time frame: Start of neoadjuvant therapy to the end of adjuvant therapy (weeks 2-28)

    Statin-enhanced toxicity of standard-of-care regimen, specifically grade 3 or 4 adverse events, as per Common Terminology Criteria for Adverse Events (CTCAE) version 6.0, warranting dosage modification or stoppage of interventional drug or chemotherapy. CTCAE grading is from 1 to 5, while grade 1 is the least severe (mild) and grade 5 is the most severe (death).

  2. 2-year EFS

    Time frame: Elapsed time from date of randomization to date of recurrence or death, within 2 years from resection

    2-year event-free-survival (EFS), defined as elapsed time from date of randomization to date of recurrence (local or distant) or death, occurring after resection

Study contacts

Contact information is provided by the study sponsor or research team.

Lorenzo Edwin Ferri, MD, PhD

CONTACT

[email protected]

514-934-1934 ext. 42835

Sponsors and collaborators

Lead sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Other

Registry information

Official study title

RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial: A Phase II Randomized Open-Label Trial of Perioperative Simvastatin Plus Standard-of-Care Systemic Therapy in Gastroesophageal Adenocarcinoma

Acronym: RESTAGE

Important dates

Study start
2027
Primary completion
2029
Study completion
2031
First posted
Jun 4, 2026
Registry last updated
Jul 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.